Plant a garden and you learn an annoying truth fast: weeds do not need your permission, your schedule, or even basic decency. High-grade serous ovarian cancer behaves with a similar lack of manners. It grows quietly, spreads early, and by the time doctors spot it, the garden often needs more than a tidy trim.
The usual approach is still serious business: chemotherapy, surgery when possible, and newer tools like PARP inhibitors or targeted drugs for selected patients. But a new pilot study asks a rude little question: what if part of the problem is that we keep feeding the weeds right before we spray them?
The Uncomfortable Little Insulin Question
The paper highlighted in Cancer Discovery reports that patients with advanced ovarian cancer who fasted around chemotherapy had lower insulin levels and better outcomes than patients who ate normally (DOI: 10.1158/2159-8290.CD-NW2026-0058).
The underlying idea is not mystical wellness confetti. It is metabolism.
Insulin is best known as the hormone that helps move sugar from blood into cells. But insulin and its close cousin IGF-1 also act like growth signals. In normal tissue, that is useful. In cancer, it can be like handing a motivational poster to a burglar.
This trial tested short-term fasting in newly diagnosed advanced high-grade serous ovarian cancer, the most common and deadliest epithelial ovarian cancer subtype. Patients received carboplatin and paclitaxel before surgery. One group ate freely. The fasting group limited intake to a maximum of 350 calories per day starting 36 hours before chemotherapy and continuing until 24 hours after treatment, then returned to regular eating between cycles.
That matters. This was not “live on vibes and lemon water forever.” It was a tightly timed metabolic intervention around chemo.
Chemo Meets a Hungrier Tumor
After three chemotherapy cycles, insulin levels rose in the free-diet group but fell slightly in the fasting group. More eyebrow-raising: among patients who had surgery after chemo, complete or near-complete pathologic response appeared in 58.8% of the fasting group versus 17.6% of the free-diet group. Median progression-free survival was also reported as longer: 38 months versus 24 months after about 18 months of median follow-up.
That is the kind of result that makes researchers sit up straighter and everyone else ask, “Wait, is lunch cancelled?”
Not so fast. This was a small, single-center pilot study. Eighteen patients per arm completed three cycles and were analyzed. That is enough to generate a serious hypothesis, not enough to rewrite oncology nutrition advice with a Sharpie.
Still, the biology is plausible. Fasting may lower insulin and IGF-1 signaling, push normal cells into a more stress-resistant mode, and leave cancer cells - those overachieving little rebels - less able to cope with chemotherapy. Some preclinical work suggests fasting can also reshape immune activity, possibly making the tumor neighborhood less friendly to cancer’s usual shady business.
Haven’t We Heard This Before?
Yes, and that is where the contrarian eyebrow goes up.
Fasting during chemotherapy has been studied before, mostly in small trials and mixed cancer populations. A 2022 review in Advances in Nutrition found that periodic fasting may improve chemotherapy effectiveness, reduce side effects, and lower cancer-promoting biomarkers such as insulin, but emphasized that larger trials are needed (PMCID: PMC8970823, DOI: 10.1093/advances/nmab132).
A randomized crossover pilot study in breast and ovarian cancer found that short-term fasting around chemotherapy was feasible and appeared to reduce quality-of-life deterioration during treatment (PMCID: PMC5921787, DOI: 10.1186/s12885-018-4353-2). Another review in CA: A Cancer Journal for Clinicians argued that intermittent fasting has promising mechanisms, but human evidence remains early and uneven (DOI: 10.3322/caac.21694).
So the new ovarian cancer data do not arrive from outer space wearing a lab coat. They fit into a growing pattern. But patterns are not proof. Biology loves a plot twist, usually right after you have made a confident statement in public.
The Real-World “Maybe” Is Big
If larger studies reproduce this, short-term fasting could become a low-cost add-on to standard chemotherapy. That is the intriguing part. Not a $400,000 molecule. Not a machine that looks like it was borrowed from a sci-fi villain. A scheduled dietary strategy.
But safety is the line in permanent marker. Fasting during chemotherapy is not for everyone. People with diabetes, malnutrition, eating disorders, frailty, kidney problems, or certain medication needs may face real risks. Even in the study, patients had eligibility rules and medical monitoring. Oncology dietitians exist for a reason, and that reason is not to ruin your soup.
The best takeaway is not “skip meals to fight cancer.” It is: metabolism may be a treatment partner, and ovarian cancer may care very much about the hormonal weather surrounding chemotherapy.
For now, fasting around chemo belongs in the “promising, supervised, needs bigger trials” bucket. But it is a bucket worth watching. Sometimes the overlooked angle is not a new drug target hiding in a gene panel. Sometimes it is the question of whether the tumor gets room service before chemo shows up.
References
-
Ovarian Cancer Outcomes Improve with Fasting During Chemotherapy. Cancer Discovery. 2026. DOI: 10.1158/2159-8290.CD-NW2026-0058
-
Gabel K, Cares K, Varady K, Gadi V, Tussing-Humphreys L. Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy. Advances in Nutrition. 2022;13(2):667-680. DOI: 10.1093/advances/nmab132, PMCID: PMC8970823
-
Bauersfeld SP, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. 2018;18:476. DOI: 10.1186/s12885-018-4353-2, PMCID: PMC5921787
-
Nencioni A, Caffa I, Cortellino S, Longo VD. Intermittent fasting in the prevention and treatment of cancer. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249. DOI: 10.3322/caac.21694
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.